-
Views
-
Cite
Cite
Nicholas F. Marko, Robert J. Weil, The molecular biology of WHO grade I astrocytomas, Neuro-Oncology, Volume 14, Issue 12, December 2012, Pages 1424–1431, https://doi.org/10.1093/neuonc/nos257
- Share Icon Share
Abstract
World Health Organization (WHO) grade I astrocytomas include pilocytic astrocytoma (PA) and subependymal giant cell astrocytoma (SEGA). As technologies in pharmacologic neo-adjuvant therapy continue to progress and as molecular characteristics are progressively recognized as potential markers of both clinically significant tumor subtypes and response to therapy, interest in the biology of these tumors has surged. An updated review of the current knowledge of the molecular biology of these tumors is needed. We conducted a Medline search to identify published literature discussing the molecular biology of grade I astrocytomas. We then summarized this literature and discuss it in a logical framework through which the complex biology of these tumors can be clearly understood. A comprehensive review of the molecular biology of WHO grade I astrocytomas is presented. The past several years have seen rapid progress in the level of understanding of PA in particular, but the molecular literature regarding both PA and SEGA remains nebulous, ambiguous, and occasionally contradictory. In this review we provide a comprehensive discussion of the current understanding of the chromosomal, genomic, and epigenomic features of both PA and SEGA and provide a logical framework in which these data can be more readily understood.
- pulmonary artery stenosis
- mutation
- astrocytoma
- immunologic adjuvants
- pharmaceutical adjuvants
- chromosomes
- genes
- genome
- medline
- molecular biology
- p-aminosalicylic acid
- technology
- world health organization
- neoplasms
- pharmacology
- aminosalicylic sodium
- pilocytic astrocytoma
- astrocytoma, subependymal giant cell
- braf gene